Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
CYTK reports a wider-than-expected Q4 loss as operating expenses increase. CYTK is gearing up to launch lead candidate aficamten upon…
39,900€
Echtzeit-Aktienkurs Cytokinetics Inc.
Bid:
Ask:
Nachrichten zur Cytokinetics Inc. Aktie
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -3.28% and 14.21%, respectively, for the quarter ended December 2024. Do the…
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release
Cytokinetics (CYTK) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
Cytokinetics jumps amid renewed takeover speculation
…
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart…
Stifel starts Cytokinetics stock with Buy, $80 target By Investing.com
Stifel starts Cytokinetics stock with Buy, $80 target…
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs (NASDAQ: CYTK) finished the trading week in style, as its stock price outperformed many other titles by…
Cytokinetics stock rises on Sanofis rights acquisition By Investing.com
Cytokinetics stock rises on Sanofis rights acquisition…
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will…
Bayer: 560-Millionen-Euro-Deal für Herz-Kreislauf-Markt
Bayer hat eine exklusive Lizenzvereinbarung mit Cytokinetics für das Herzmedikament Aficamten abgeschlossen, das gegen hypertrophe Kardiomyopathie (HCM) eingesetzt wird. Der…
Bayer: Spannender Deal in Japan – die Details
Der DAX-Konzern Bayer stärkt sein Pharma-Portfolio. Mit dem US-Biotechnologie-Unternehmen Cytokinetics konnten die Leverkusener eine exklusive Lizenzvereinbarung für Aficamten in Japan…
Bayer: Spannender Deal in Japan – die Details
Der DAX-Konzern Bayer stärkt sein Pharma-Portfolio. Mit dem US-Biotechnologie-Unternehmen Cytokinetics konnten die Leverkusener eine exklusive Lizenzvereinbarung für Aficamten in Japan…
Bayer acquires rights to Cytokinetics heart drug in Japan By Reuters
Bayer acquires rights to Cytokinetics heart drug in Japan…
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data…
Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript
…
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional…
Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities
…
Cytokinetics, Incorporated (CYTK) Q2 2024 Earnings Call Transcript
…
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission…
Cytokinetics Aficamten: Heartfelt Potential Amid Market Woes
…
Cytokinetics executive sells over $390k in company stock By Investing.com
Cytokinetics executive sells over $390k in company stock…
Cytokinetics CEO sells over $1.1 million in company stock By Investing.com
Cytokinetics CEO sells over $1.1 million in company stock…
Cytokinetics Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing…
BofA cuts Cytokinetics shares target amid near-term uncertainties By Investing.com
BofA cuts Cytokinetics shares target amid near-term uncertainties…
Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript
…
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM…
Cytokinetics maintains $99 target on positive trial data By Investing.com
Cytokinetics maintains $99 target on positive trial data…
Cytokinetics, Incorporated: Buyout Speculation Persists
…
Schlussglocke: Nasdaq verliert - Gerüchte um Cytokinetics und Shockwave Medical, Tesla gibt ...
Die wichtigsten amerikanischen Indizes befinden sich weiter in Schlagdistanz zu den bisherigen Bestmarken. Dow Jones und Nasdaq 100 mussten dennoch…
Schlussglocke: Nasdaq verliert – Gerüchte um Cytokinetics und Shockwave Medical, Tesla gibt Gas
Die wichtigsten amerikanischen Indizes befinden sich weiter in Schlagdistanz zu den bisherigen Bestmarken. Dow Jones und Nasdaq 100 mussten dennoch…
Schlussglocke: Nasdaq verliert – Gerüchte um Cytokinetics und Shockwave Medical, Tesla gibt Gas
Die wichtigsten amerikanischen Indizes befinden sich weiter in Schlagdistanz zu den bisherigen Bestmarken. Dow Jones und Nasdaq 100 mussten dennoch…
Cytokinetics: CEO Talks Down Buyout Prospects
…
Earnings call: Cytokinetics sees positive phase 3 results for aficamten By Investing.com
Earnings call: Cytokinetics sees positive phase 3 results for aficamten…
Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript
…